Tuhura Biosciences, Inc. (HURA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on September 11, 2025, covering events occurring on September 5, 2025. Tuhura Biosciences, Inc. is a Nevada corporation reporting on the Nasdaq Capital Market. The filing details the finalization of a private placement offering and related warrant amendments.
Key Financial Metrics and Transaction Details
- Offering Structure: A private placement of 4.76 million shares of Common Stock and warrants to purchase an equal number of shares at an exercise price of $3.3125.
- Total Offering Amount: Approximately $12.6 million.
- Effective Price: $2.65 per share and accompanying warrant.
- Funding Status: Approximately $8.9 million was funded through July 24, 2025. The remaining balance was subject to a final tranche requirement.
- Final Tranche Execution: On September 5, 2025, Deferral Investors purchased an aggregate of $3.2 million of the Final Tranche Offering Amount.
- Warrant Extension: In exchange for the final funding, the Company extended the expiration dates of 1.5 million shares of "2024 Warrants" (issued in a 2024 convertible note placement) to December 31, 2030.
Material Changes and Agreements
The primary material change is the execution of Final Purchase Agreements and Warrant Amendment Agreements with four Deferral Investors: Pranabio Investments LLC, Garden Street House, LLC, Thomas C. Mollick, and Matthew Nachtrab. While the Securities Purchase Agreement required approximately $3.7 million to be funded by December 31, 2025, the investors committed to funding $3.2 million immediately on September 5, 2025, in exchange for the warrant extension.
Guidance, Outlook, and Risks
The filing does not provide specific forward-looking guidance, revenue projections, or management commentary regarding future operational outlook. The document focuses strictly on the legal and financial terms of the capital raise and warrant amendments. No specific risks or contingencies beyond the standard terms of the agreements are detailed in this summary text.
Investor Verification Checklist
- Verify the exact amount of the remaining unfunded portion of the Final Tranche Offering Amount (originally $3.7 million required, $3.2 million funded).
- Review the attached Exhibits 10.1 (Final Closing Agreement) and 4.2 (Warrant Amendment Agreement) for specific terms regarding the 1.5 million extended warrants.
- Confirm the dilution impact of the 4.76 million new shares and the associated warrants on existing shareholders.
- Check subsequent filings to determine if the remaining $0.5 million of the Final Tranche was funded or if the agreement was further amended.